Oneview Healthcare Launches $19M Placement to Fund AI Assistant and US Deployments

Oneview Healthcare launches $19 million placement to accelerate AI development and customer deployments

Global healthcare technology company Oneview Healthcare (ASX: ONE) has received firm commitments for a $19 million institutional placement, demonstrating strong investor confidence despite challenging global capital market conditions. The placement was upsized due to robust demand from both existing shareholders and new international investors, with major shareholder Manderrah Pty Ltd committing $7 million, subject to shareholder approval.

The placement will issue 100 million new CHESS Depositary Interests (CDIs) at $0.19 per CDI, representing a 7% discount to the last closing price on 13 March 2026. This capital raising positions Oneview to strengthen its balance sheet while accelerating deployment momentum across new and existing customers, converting signed pipeline into live, revenue-generating endpoints.

How placement proceeds will fund Oneview’s growth strategy

The capital raising will support four primary strategic initiatives critical to Oneview’s growth trajectory. Major US health systems place significant emphasis on balance sheet strength during vendor evaluation processes, making this capital injection increasingly important as the company scales in its core market.

Proceeds will fund continued deployment momentum, enabling the conversion of Oneview’s signed pipeline into operational, revenue-generating endpoints across both new and existing customer sites. The funds will also support the advancement of Ovie, the company’s AI-powered virtual patient assistant, alongside improvements to the AI software development lifecycle and automation initiatives designed to drive business efficiency as operations scale.

SPP offers existing securityholders participation opportunity

Alongside the institutional placement, Oneview will offer eligible securityholders in Australia, New Zealand and Ireland the opportunity to participate in a Security Purchase Plan (SPP) targeting up to approximately $2 million in additional capital.

The SPP will be offered at the same issue price as the institutional placement ($0.19 per CDI), with eligible holders on the register as at 7.00pm Sydney time on 13 March 2026 able to subscribe for up to $30,000 of new CDIs. The company reserves the right to increase the SPP size or scale back applications at its discretion. The SPP booklet is expected to be dispatched on 25 March 2026, with the offer closing on 10 April 2026.

What is a placement and why companies use them to raise capital

A share placement is a capital raising method where a company issues new shares to institutional and sophisticated investors at a set price, typically at a discount to the current market price. Placements are frequently used by ASX-listed companies because they can be executed quickly, attract institutional support, and cause minimal disruption to existing operations compared to other capital raising methods.

Oneview’s placement is structured across two tranches. Tranche 1 will raise $12 million through the issue of 63,157,895 new CDIs under the company’s existing ASX Listing Rule 7.1 placement capacity. Tranche 2 will raise $7 million through the issue of 36,842,105 new CDIs to major shareholder Manderrah Pty Ltd, subject to shareholder approval at an extraordinary general meeting expected in May 2026.

This two-tranche structure is necessary because Tranche 2 involves a related party (the company’s largest shareholder), requiring shareholder approval under ASX rules. The SPP component allows retail investors to participate on equal pricing terms, ensuring existing securityholders can maintain their proportional ownership if they choose.

CEO outlines strategic positioning amid growing healthcare technology demand

CEO James Fitter positioned the successful Oneview Healthcare $19 million placement within the context of accelerating structural pressures facing global health systems and growing demand for technology-enabled efficiency solutions.

James Fitter, CEO

“In an environment where global capital markets remain distinctly risk‑off, affected by geopolitical instability in the Middle East and broader macroeconomic uncertainty, the successful completion of this $19 million institutional placement represents a strong endorsement of Oneview’s strategy, execution, and long‑term potential.

Health systems continue to face significant structural pressures, including rising patient expectations, acute workforce shortages, and the demands of ageing populations. As virtual care adoption accelerates, the need for technology‑enabled efficiency is increasing. Oneview’s Connected Care Experience platform is becoming progressively more strategic in this context, supporting patient empowerment, reducing clinical burden, and enabling the orchestration of digitally supported models of care.

The funds raised through the Placement will further strengthen the Company’s balance sheet at a time of growing market opportunity and continued deployment momentum across new and existing customers. This capital will also support ongoing investment in automation and AI‑enabled solutions designed to enhance operational efficiency as the business scales, including the continued development of Ovie, our AI‑powered virtual patient assistant.”

Fitter expressed particular gratitude for the strong international participation in the placement and thanked loyal securityholders for their ongoing support, emphasising the team’s commitment to executing strategy and delivering outcomes that justify investor confidence.

Key transaction dates and settlement timeline

The placement and SPP will progress according to the following indicative timetable:

1. SPP record date: Friday 13 March 2026 (7.00pm Sydney time)
2. Tranche 1 settlement: Tuesday 24 March 2026
3. Tranche 1 allotment and trading: Wednesday 25 March 2026
4. SPP booklet dispatch and offer opens: Wednesday 25 March 2026
5. SPP offer closes: Friday 10 April 2026 (5.00pm Sydney time)
6. SPP allotment: Friday 17 April 2026
7. SPP CDIs commence trading: Monday 20 April 2026
8. Extraordinary General Meeting: Expected May 2026
9. Tranche 2 settlement and allotment: Expected May 2026

All dates are indicative and subject to change at the company’s discretion, subject to ASX Listing Rules and the Corporations Act 2001 (Cth).

Investment outlook and deployment momentum

The combination of balance sheet strengthening, deployment momentum and AI innovation positions Oneview to capture growing healthcare technology demand while meeting stringent US health system vendor requirements. With total capital of up to approximately $21 million (including the SPP target), the company aims to convert its signed pipeline into operational endpoints while advancing product development initiatives.

MST Financial Services Pty Limited acted as Lead Manager and bookrunner to the placement. The capital raising occurs against a backdrop of structural healthcare pressures, rising patient expectations, acute workforce shortages and accelerating virtual care adoption, trends that continue to drive demand for technology-enabled efficiency solutions across Oneview’s target markets.

The successful completion of this placement in a risk-off capital markets environment, combined with strong international participation and major shareholder commitment, signals institutional confidence in Oneview’s strategy and execution capability as the business scales.

Want the Next Healthcare Tech Winner in Your Inbox?

Join 20,000+ investors receiving FREE breaking ASX news delivered within minutes of release, complete with expert analysis. Big News Blast covers healthcare technology, medical innovation and digital health breakthroughs the moment announcements drop. Click the “Free Alerts” button to get ahead of the market.